New Omicron subvariant largely evades neutralising antibodies: Lancet study
indiatimes.com
science
2022-10-17 07:45:00

Image used for representational purpose onlyThe BA.2.75.2 variant of Omicron largely evades neutralising antibodies in the blood and is resistant to several COVID-19 antibody therapies, according to a study published in The Lancet Infectious Diseases journal. The findings by researchers at Karolinska Institutet, Sweden suggest a risk of increased SARS-CoV-2 infections this winter, unless the new updated bivalent vaccines help to boost immunity in the population. 
 "While antibody immunity is not completely gone, BA.
